Abstract: Provided is an orally disintegrating tablet comprising brexpiprazole or a salt thereof that rapidly disintegrates in the oral cavity while having hardness suitable for practical use. More specifically, provided is an orally disintegrating tablet comprising (A) brexpiprazole or a salt thereof, (B) D-mannitol, (C) partially pregelatinized starch, and (D) a lubricant.

Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.

Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.

Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.

Abstract: Disclosed is a method for stabilizing a solid pharmaceutical preparation containing a pharmacological substance and sodium lauryl sulfate, the method comprising incorporating into the preparation at least one member selected from the group consisting of neutral salts, basic salts and basic substances. The preparation containing sodium lauryl sulfate prepared by the method of the invention has superior performance, including high storage stability, suppression of discoloration and deterioration, and prevention of change in its properties, such as the dissolution rate of pharmacological substance from the preparation.

Abstract: An antenna includes a substrate made of a dielectric material, a first different dielectric constant region having a dielectric constant different from a dielectric constant of said substrate provided in said substrate, and a first antenna element provided on a front surface of said substrate.

Abstract: Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

Abstract: A small photodetector type microphone (10) exhibiting excellent directivity without requiring any mirror surface. A diaphragm (27) vibrates in response to a sound pressure. An optical waveguide (28) is formed along the diameter of the diaphragm (27) and integral vibration of the optical waveguide (28) and the diaphragm (27) causes a variation in the quantity of light leaking from the optical waveguide (28) to the outside thus causing a variation in the quantity of light being transmitted across the optical waveguide (28). The optical waveguide (28) has one end side for introducing light into a light emitting elements (20) and the other end side for delivering light to a light receiving element (24). The light receiving element (24) outputs an electric signal related to the quantity of incident light.

Abstract: A small photodetector type microphone (10) exhibiting excellent directivity without requiring any mirror surface. A diaphragm (27) vibrates in response to a sound pressure. An optical waveguide (28) is formed along the diameter of the diaphragm (27) and integral vibration of the optical waveguide (28) and the diaphragm (27) causes a variation in the quantity of light leaking from the optical waveguide (28) to the outside thus causing a variation in the quantity of light being transmitted across the optical waveguide (28). The optical waveguide (28) has one end side for introducing light into a light emitting elements (20) and the other end side for delivering light to a light receiving element (24). The light receiving element (24) outputs an electric signal related to the quantity of incident light.

Abstract: Disclosed is a method for stabilizing a solid pharmaceutical preparation containing a pharmacological substance and sodium lauryl sulfate, the method comprising incorporating into the preparation at least one member selected from the group consisting of neutral salts, basic salts and basic substances. The preparation containing sodium lauryl sulfate prepared by the method of the invention has superior performance, including high storage stability, suppression of discoloration and deterioration, and prevention of change in its properties, such as the dissolution rate of pharmacological substance from the preparation.

Abstract: Disclosed is a cilostazol dry coated tablet which comprises (A) a core portion containing cilostazol and (B) an outer layer portion containing cilostazol, a water-insoluble substance and a hydrophilic hydrogel forming substance. Said tablet is a new type of preparation capable of suppressing an undesirable rise of the maximum blood concentration of cilostazol while it maintains an adequate blood concentration of cilostazol by continuously releasing, for hours, only a required amount of cilostazol for obtaining a desired drug efficacy of cilostazol.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, hydroxyl or lower alkoxy, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen, lower alkyl, amino-lower-alkyl or acylamino-lower-alkyl, R.sup.5 is hydrogen, lower alkyl or aralkyl which may be substituted, R.sup.6 is hydroxyl, lower alkoxy, amino or lower alkylamino, and m and n each means 1 or 2, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, hydroxyl or lower alkoxy, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen, lower alkyl, amino-lower-alkyl or acylamino-lower-alkyl, R.sup.5 is hydrogen, lower alkyl or aralkyl which may be substituted, R.sup.6 is hydroxyl, lower alkoxy, amino or lower alkylamino, and m and n each means 1 or 2, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: Novel compounds of the formula: ##STR1## wherein R is phenyl-C.sub.1-6 alkyl, and salts thereof, have intraocular pressure depressant action.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represent hydrogen, halogen, lower alkyl, hydroxyl, lower alkyloxy or aralkyloxy, or R.sup.1 and R.sup.2 jointly represent lower alkylenedioxy; R.sup.3 and R.sup.4 each represent hydrogen or lower alkyl; R.sup.5 represents hydrogen, lower alkyl or --CH.sub.2 SR.sup.7 (R.sup.7 represents hydrogen or acyl); R.sup.6 represents hydrogen or acyl, or R.sup.6 and R.sup.7 jointly represent a single bond; X represents --CH.sub.2 --, --O-- or >N--R.sup.8 (R.sup.8 represents hydrogen, acyl or lower alkyl); and n represents 2, 3 or 4, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: Useful intermediates for the preparation of hypotensives and inhibitors of angiotensin converting enzymes are L-alanyl-N-(indan-2-yl)glycine, its lower alkyl esters and the salts thereof.

Abstract: Novel peptide derivatives, inclusive of salts thereof, of the formula ##STR1## wherein A represents monocyclic or bicyclic hydrocarbon group, R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1-4 alkyl or phenyl-C.sub.1-4 alkyl, and R.sup.2, R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-4 alkyl, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: Novel 1,2-dihydronaphthalene derivatives of the formula ##STR1## wherein A is a di-lower alkylamino group or a 5- to 7-membered cyclic amino group which may contain one oxygen atom and n is 2 or 3, and its salts have excellent pharmacological activities such as vasodilator, hypotensive and cerebral blood flow increasing actions.

Abstract: Novel 1,2-dihydronaphthalene derivatives of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently of each other, are hydrogen, nitro, amino, halogen, or hydroxyl which may be protected, and R.sup.3 is a piperazinyl or morpholino group which may be substituted by lower alkyl, aralkyl, carboxylic acid-derived acyl, lower alkoxycarbonyl-lower alkyl or cycloaminocarbonyl-lower alkyl, and its salts have excellent pharmacological activities such as vasodilator and cerebral blood flow increasing activities.

Abstract: New isochroman derivatives which may be represented by general formula [I] ##STR1## wherein R.sup.1 is hydrogen atom, a lower alkoxy group or hydroxyl group and R.sup.2 is a lower alkoxy group or hydroxyl group; R.sup.1 and R.sup.2 may also be, connecting with each other, alkylenedioxy group; R.sup.3 is a hydrogen atom, a lower alkyl or aralkyl group and R.sup.4 is a lower alkyl or aralkyl group; R.sup.3 and R.sup.4 may also be groups which, taken together with the adjacent nitrogen atom, form a cyclic amino group; n means 1 or 2, and pharmacologically acceptable salt thereof have antidepressant, analgesic, diuretic, anti-inflammatory, muscle relaxing, vasodilator, hypotensive and other pharmacologic activities for mammals.